(12) **Translation of European patent specification**

(11) **NO/EP 2419108 B1**

NORWAY

(19) NO

(51) Int Cl.
A61K 31/56 (2006.01)
A61K 9/06 (2006.01)
A61K 9/20 (2006.01)
A61K 31/57 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.12.19
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.08.17
(86)	European Application Nr.	10717084.7
(86)	European Filing Date	2010.04.13
(87)	The European Application's Publication Date	2012.02.22
(30)	Priority	2009.04.14, US, 169149 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR
	Designated Extension States:	AL BA ME RS
(73)	Proprietor	Laboratoire HRA Pharma, 15, rue Béranger, 75003 Paris, FR-Frankrike The United States of America, as represented by The Secretary, Department of Health and Human Services, Office of Technology Transfer National Institutes of Health 6011 Executive Boulevard, Suite 325 MSC 7660, Bethesda, MD 20892-7660, US-USA
(72)	Inventor	ULMANN, André, 23 rue Pascal, F-75005 Paris, FR-Frankrike GAINER, Erin, 18 rue de l'Atlas, F-75019 Paris, FR-Frankrike BLITHE, Diana, 2319 Deckman Lane, Silver Spring, MD 20906, US-USA NIEMAN, Lynette, 8220 Hamilton Spring Ct, Bethesda, MD 20817, US-USA MATHE, Henri Camille, 86 rue Marcadet, 75018 Paris, FR-Frankrike
(74)	Agent or Attorney	Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge

(54) Title **METHOD FOR ON-DEMAND CONTRACEPTION**

(56) References Cited:

WO-A1-00/09136
WO-A2-2008/079245
WO-A2-2008/122439
WO-A2-2010/066749
ORIHUELA PEDRO A: "Ulipristal, a progesterone receptor antagonist as a contraceptive and for the treatment of uterine fibroids" CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 8, no. 10, 1 October 2007 (2007-10-01), pages 859-866, XP009115744 ISSN: 1472-4472

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (http://worldwide.espacenet.com) or via the search engine on our website here: https://search.patentstyret.no/

PATENTKRAV

1. Fremgangsmåte for prevensjon som omfatter at det til en kvinne oralt administreres en form med umiddelbar frigjøring som omfatter ulipristalacetat eller en metabolitt derav i en mengde på 30 mg i løpet av 120 timer etter samleie.

2. Fremgangsmåte ifølge krav 1, hvor den faste formen blir administrert innen 72 timer etter samleie.

3. Fremgangsmåte ifølge krav 1 eller 2, hvor formen med umiddelbar frigjøring er en tablett.

4. Fremgangsmåte ifølge krav 3, hvor tabletten omfatter et fortynningsmiddel, et bindemiddel og et desintegreringsmiddel.

5. Fremgangsmåte ifølge hvilket som helst av kravene 1-4, hvor metabolitten er valgt fra gruppen bestående av CDB-3877, CDB-3963, CDB-3236 og CDB-4183.

6. Fremgangsmåte ifølge hvilket som helst av kravene 1-5, hvor administreringen blir gjentatt minst to ganger i en måned.